Home・Listă Acțiuni・Axsome Therapeutics Inc

Axsome Therapeutics Inc

Închisă

SectorSănătate

212.12 1.01

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

206.71

Maxim

218

Indicatori cheie
By Trading Economics
Venit	-36M -65M
Vânzări	-4.8M 191M
EPS	-1.26
Marjă de profit	-33.756
Angajați	1,220
EBITDA	-36M -61M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+35.28% upside

Dividende
By Acuity
Următoarele câștiguri	10 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	2.6B 12B
Deschiderea anterioară	211.11
Închiderea anterioară	212.12

Sentimentul știrilor

By Acuity

58%

42%

276 / 340 Clasament în Healthcare

Axsome Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 22:16 UTC

Axsome Therapeutics Inc shares are higher in after-market hours, despite no specific news. The stock showed unusual activity amid broader market dynamics.

31 iul. 2026, 22:01 UTC

Axsome Therapeutics Inc shares are higher in after-market trading, reflecting strong interest despite no specific news. The stock remains below its 20-day moving average.

30 iul. 2026, 19:28 UTC

Axsome Therapeutics Inc is rising during Thursday's session, reversing four consecutive lower closes. The stock remains below its 20-day moving average.

29 iul. 2026, 22:01 UTC

Axsome Therapeutics Inc shares are lower in after-market trading, closing below their 20-day moving average amid broader market caution and geopolitical tensions.

28 iul. 2026, 19:51 UTC

Axsome Therapeutics Inc shares are lower today, breaking a trend of higher daily closes amid broader market declines, particularly in Asian markets.

27 iul. 2026, 20:14 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a three-session trend. No specific news was identified to explain the movement.

24 iul. 2026, 23:51 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, reflecting a notable decline since Friday's close, with no specific news identified.

22 iul. 2026, 19:11 UTC

Axsome Therapeutics Inc shares are trading higher during Wednesday's session, reaching a high earlier before pulling back slightly amid increased market volume.

21 iul. 2026, 19:51 UTC

Social Media

News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target, contributing to a rise in shares today.

20 iul. 2026, 21:21 UTC

News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target. Shares are trading higher in after-market hours.

Comparație

Modificare preț

Axsome Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

35.28% sus

Prognoză pe 12 luni

Medie 285.5 USD 35.28%

Maxim 380 USD

Minim 242 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAxsome Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 14 analiști care au acordat evaluări ale acțiunilor Axsome Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

276 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.